Related Experiment Video
Updated: Mar 12, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
14.0K
Prostate cancer perspectives after chaarted: Optimizing treatment sequence.
Sergio Vázquez Estévez1, Urbano Anido Herranz2, Ovidio Fernández Calvo3
1Medical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain.
Critical Reviews in Oncology/Hematology
|November 9, 2016
Summary
New prostate cancer treatments improve survival. Adding docetaxel early benefits patients with hormone-sensitive disease, changing treatment sequences for metastatic prostate cancer.
Area of Science:
- Oncology
- Urology
Background:
- Prostate cancer is a leading cancer in men.
- Historically, treatment options were limited to androgen-deprivation therapy and docetaxel for castration-resistant disease.
Purpose of the Study:
- To review treatment options for hormone-sensitive prostate cancer progressing after initial docetaxel therapy.
- To propose an algorithm for sequencing advanced prostate cancer treatments.
Main Methods:
- Review of recent clinical trials (Chaarted, Stampede) and emerging therapies.
- Analysis of survival data and treatment efficacy for metastatic prostate cancer.
Main Results:
- Recent studies support early docetaxel administration in metastatic hormone-sensitive prostate cancer.
- New drugs like abiraterone and enzalutamide offer improved safety and efficacy.
Conclusions:
- Treatment sequencing is crucial for optimizing outcomes in advanced prostate cancer.
- An evidence-based algorithm can guide personalized treatment strategies.
Related Concept Videos
01:21Cancer Survival Analysis
808
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
808
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K